US OptionsDetailed Quotes

ADVM241220C7000

Watchlist

0.52
0.000.00%

15min DelayClose Dec 11 16:00 ET

0.00High0.00Low

Adverum Biotechnologies Stock Discussion

Stock_Drift

Nov 15 16:17

After Hours Ticks. 5:16pm 11/15🦌

$Scorpius Holdings (SCPX.US)$ $Perspective Therapeutics (CATX.US)$ $Turbo Energy (TURB.US)$ $Adverum Biotechnologies (ADVM.US)$ $NFT Ltd (MI.US)$ $Xylo Technologies (XYLO.US)$ $Lipocine (LPCN.US)$ $Massimo (MAMO.US)$ $China Jo-Jo Drugstores (CJJD.US)$ $Edesa Biotech (EDSA.US)$ $Atara Biotherapeutics (ATRA.US)$ $Eterna Therapeutics (ERNA.US)$ $DDC Enterprise (DDC.US)$
📊⚡️📊

Trytosaveabit

Aug 1 07:00

News

$Adverum Biotechnologies (ADVM.US)$ Reuters· just
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet AMD

Jaguar8

Jul 17 02:57

NEWS

$Adverum Biotechnologies (ADVM.US)$
Adverum Biotechnologies Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting
Adverum Biotechnologies (Nasdaq: ADVM) presented positive 26-week interim results from the LUNA Phase 2 trial of Ixo-vec for wet AMD at the 2024 ASRS Annual Meeting. Key findings include:
1. The 6E10 dose with local prophylaxis was selected for Phase 3 trials.
2. 76% of 6E10 patients were injection-fr...

Jaguar8

Apr 25 15:10

$Adverum Biotechnologies (ADVM.US)$
NEWS
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting

Trytosaveabit

Feb 8 06:05

Update

$Adverum Biotechnologies (ADVM.US)$ Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
4 MINUTES AGO, 7:00 AM EST
VIA GLOBENEWSWIRE
– Both dose levels (2E11 & 6E10) demonstrate potential best-in-class clinical activity in hard-to-treat patients including treatment burden reduction and maintenance of both visual acuity and anatomic endpoints –
– Preliminary safety data support a favorable benefit-risk pr...

QMengColdJoke

Feb 5 14:44

Sold half at 1.8 but chart look good

$Adverum Biotechnologies (ADVM.US)$ 2 insiders buy 200k cash in private placement, settlement Feb 8 the data release day. Lol, simple insider trading. Are they stupid? Anyway, there won’t be surprise for the data release, should be safe pass.
Just I am afriad the 1.2 private offering deal (typically 20% to 10% off to fair value) will pin the price to 1.4 to 1.6 area. Cashless warrant is bad for common investors. Also attract too many day traders. won’t last l...

BadDuck74

Feb 5 07:38

$Adverum Biotechnologies (ADVM.US)$Adverum Biotechnologies Has Agreed To Sell Approximately 106.25M Shares In A Private Placement At $1.20/Share With Gross Proceeds Of Approximately $127.5M; Pro Forma Cash And Investments Expected To Fund Current Operating Plan Into Late 2025

MangoXoXo

Feb 5 07:36

$Adverum Biotechnologies (ADVM.US)$ 2 dollars?

JuliaBiswas

Feb 5 04:12

Who is the winner today, after the poditive data announced on 03 Feb
$EyePoint Pharmaceuticals (EYPT.US)$
$Adverum Biotechnologies (ADVM.US)$
$Regenxbio (RGNX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Kodiak Sciences (KOD.US)$

QMengColdJoke

Feb 2 08:51

feels like insider action.

$Adverum Biotechnologies (ADVM.US)$ I’ll probably sell most position at $2. I feels like phase 2 is great, and they are working with some IB to do stock offering once news is out.

No comment yet